The Tamesis
Novo Nordisk said on Tuesday it would cut prices of Wegovy and Ozempic by up to 50% starting next year, underscoring growing competition among drug companies for customers seeking weight-loss drugs.
The Danish drugmaker said it plans to offer the drugs for $675 a month starting in January 2027, which would represent a 50% price drop for Wegovy and a 35% price drop for Ozempic. Novo Nordisk will also sell Rybelsus, a drug that treats type 2 diabetes in adults and is sometimes used for weight loss, for the same price.
Novo Nordisk’s decision comes as it competes with Eli Lilly, which sells injectable drugs Mounjaro and Zepbound commonly used for weight loss, and with suppliers of other so-called GLP-1 treatments that are about to hit the market.
Wegovy and Ozempic are among them dozens of drugs Sold at discounted price Trump administrationis a new online platform launched by the Trump administration that allows consumers to purchase about 40 types of medicines directly at lower prices.
In November, Novo Nordisk also announced New pricing plan Wegovy and Ozempic can reduce costs for some customers.
The company on Tuesday framed its decision as a way to improve affordability, noting in a news release that it hopes to lower out-of-pocket costs for customers with high-deductible insurance plans.
“Private and public payers, as well as patients, want access to this service and have been calling for lower list prices,” Jamey Miller, executive vice president of Novo Nordisk’s U.S. operations, said in a statement.
The drug company said the price cuts would not affect its “direct-to-patient” prices, the discounted prices some manufacturers offer directly to consumers.
